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Introduction 
 
Many countries have developed national strategies aimed at tackling drug-related 
problems including reducing deaths associated with drugs.  
 
These aims are shared by the World Health Organisation (WHO) and the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
 
To measure progress in reducing drug-related death (DRD) 
 
Need clear idea of what types of death are relevant so can set measurable targets.   
 
This can only be done on the basis of good, reliable information.   
 
This is also a prerequisite for measuring and monitoring DRDs.  
 
This paper explores such informational needs in national, UK and sub-national 
contexts, particularly with regard to a 'headline' indicator.   
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Information required to define DRD 
 
Definitions of drug-related mortality  
(a) direct/'acute' e.g. intoxication/overdose/poisoning by drugs; 
(b) volatile substance abuse;  
(c) indirect, including violence (homicide), traffic accidents, infectious diseases 
acquired through drug use e.g. hepatitis, HIV/AIDS.  
 
Which type(s) of death are included in a target depends on the foci of a drug strategy.   
 
Most interest in Western Europe has been on direct deaths involving consumption of 
illegal drugs. Emphasis on accidental poisonings involving opiates, cocaine, 
amphetamines, etc. consumed by 'problematic' users.   
 
Other types of death occur in relation to drugs, including intentional overdoses or 
poisonings, homicides and the sequelae of injecting drug use.  
 
More interest in prescribed medication - especially opioid substitutes (including 
methadone), antipsychotics, tranquillisers, and antidepressants - as well as 
'recreational' drugs (ecstasy, GHB).  
 
Types of death and substances of interest vary according to the country or sub-
national region, and different professional groups. 
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Setting targets for the UK Drug Strategy and sub-national policies 
 
The third aim of the UK Drugs Strategy Tackling Drugs to build a better Britain, 
published in 1998, is to 'enable people with drug problems to overcome them and live 
healthy and crime-free lives'.   
 
Performance Indicator is to reduce the number of DRDs.  One objective is to  
 
'produce a plan of action to monitor and reduce drug-related deaths, taking account of 
the recommendations from the report of the Advisory Council on the Misuse of Drugs 
[ACMD] on drug-related death'.  
 
This aim is included in the strategies of devolved administrations in Northern Ireland, 
Scotland and Wales. 
 
ACMD report (2000) stated the policies they had outlined  
 
'must be supported by a clearer definition of data needs and by reliable data which 
can help monitor policy effectiveness and focus their application. We see a 
strengthening in the data base as vital to the policy frame both in terms of national 
action, and action within communities, where ways of using the data effectively will 
need increasingly to be explored'. 
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Department of Health convened a Technical Working Group (TWG) comprised of 
experts from relevant fields to consider how best the ACMD's recommendations on 
information needs could be taken forward and to produce a definition of DRD for the 
UK Drug Strategy.  
 
4 main areas in which the TWG recommended that surveillance activities might be 
considered:  
(a) a headline indicator, i.e. 'acute' DRDs;  
(b) secondary data on blood-borne diseases, drug-related homicide, etc.;  
(c) making funding available for enhanced data such as that produced by the 
NPSAD; 
(d) local confidential inquiries.   
 
TWG's DRD definition endorsed by the full ACMD and officially adopted for use in the 
Government's Action Plan concentrated on direct unintentional deaths -  
 
'Deaths where the underlying cause is poisoning, drug abuse or drug dependence and 
where any of the substances scheduled under the Misuse of Drugs Act 1971 were 
involved''.  
 
The 1971 Act and associated secondary legislation implement the provisions of the 
UN Conventions on drugs. 
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Quality and availability of data on drug mortality 
 
Knowledge is generally poor in Europe concerning the nature of information on drug-
related mortality, and the methods of generation of such data.  
 
EMCDDA has made progress on defining and harmonising data collected from 
General Mortality Registers (GMRs) based on International Classification of Diseases 
(ICD) codes.   
 
'Sudden' deaths involving drugs are investigated by coroners in England, Wales and 
Northern Ireland, and by procurators fiscal in Scotland.  
 
The principal role of a coroner is to establish the circumstances and cause(s) of death 
and to investigate whether there was any criminal involvement.   
 
An inquest enables the coroner not only to ascertain the medical cause of death, but 
also to determine how, when and where the deceased came by his/her death, and to 
establish the particulars necessary to allow the death to be registered.  
 
Two current reviews may have an impact on the role of coroners in investigating 
deaths associated with deaths and death certification processes.   
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In Scotland, the procurator fiscal determines the cause of death based on information 
provided by the pathologist and police investigations.   
 
Coroners and procurators fiscal have a range of information on which to base 
conclusions:  
(a) results of any postmortem and toxicological examinations;  
(b) statements of witnesses, friends and relatives given to the coroner's officer 
(usually a serving or former police officer) or the police in Scotland; 
(c) medical and drug history of the individual.   
 
But such information may not be available 
 
Information on DRDs recorded by GMRs in the UK is limited to the medical certificate 
of death.  Little supplementary information 
 
Much more information is collected by other agencies but is filtered out at different 
stages in the process between an individual being found dead and their inclusion or 
not in drug strategy indicator statistics. 
 
Purpose(s) for which data are collected and the official(s) to whom they are presented 
determine what, when and how information is generated.  
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Given the focus of the coroner or procurator fiscal in only establishing the cause of 
death in a range of cases involving 'sudden' or 'suspicious' death, it cannot be 
expected that they will necessarily assemble all the information in which a drug 
epidemiologist would be interested. 
 
Much variation in terms of facilities and resources (particularly financial) between 
coroner's jurisdictions.  
 
Toxicological examinations are not routinely conducted.   
 
Only a limited range of the more common drugs may be screened for, thus missing 
less common or new ones.   
 
The extent to which there may be variation in approaches to pathology in England, 
Wales and Northern Ireland is unknown.  In Scotland most postmortems are 
conducted by only 4 academic forensic departments following agreed protocols; in 
most cases toxicological tests for drugs are conducted.   
 
There is no consensus on from what parts of the body and at what time postmortem 
samples for toxicology should be taken. This is important as these can affect the 
results.  There are disagreements as to what constitute 'fatal' levels of some drugs.     
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Whilst there may be mention in the cause of death section of the coroner's certificate 
of any drugs identified, there is usually no indication of the relative quantities or 
contribution to the death if more than one substance is identified.   
 
Typically, the coroner's certificate gives no indication of drug dependence, whether 
toxicology was carried out, how or where drugs were obtained, where drugs were 
taken or route of administration. 
 
These factors affect reliability of data provided to coroners/procurators fiscal. This 
limits the information received by GMRs, making identification of all cases relevant to 
the Drug Strategy performance indicator problematic.   
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Comparability of data 
 
Investigation 
 
Investigation of DRDs by coroners and procurators fiscal is affected by resources 
available to them, and thus to pathologists and toxicologists.   
 
Lack of standardisation in UK pathology and toxicology in the DRD field.   
 
Variation in the use of the drug-specific verdicts available to coroners not only 
between but also within jurisdictions. Training courses for coroners now make them 
aware of the need for consistency in approach and improved standards of reporting. 
 
ICD coding 
 
There were differences in the way in which ICD9 codes were applied across the UK.   
 
ICD10 was introduced 2000 and 2001. Figures published for 2001 should be on a 
consistent basis across the UK.   
 
The GMRs together with the National Programme on Substance Abuse Deaths 
(NPSAD) have collective discussions on how to apply ICD10 coding to DRDs.   
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Consistency will be reinforced through the adoption of the UK Drug Strategy definition.   
 
EMCDDA is going to produce guidance on ICD10 code interpretation. 
 
Collaboration and exchange of information    
 
EMCDDA has developed a range of standard definitions of DRDs based on ICD9 and 
ICD10 from both GMRs and Special Mortality Registers (SMRs).  
 
International conference sponsored by the Swedish National Institute of Public Health 
in April 2001.   
 
Monograph published by the European Collaborating Centres in Addiction Studies 
(ECCAS), Drug-related mortality: perspectives across Europe (in press), examines the 
epidemiology of drug-related mortality and the data on which statistics are based.  
 
Publication of DRD statistics 
 
Statistics published by GMRs in the constituent parts of the UK have been compiled 
on different bases. There have been no such statistics for Northern Ireland.  
 
There have been no UK-wide statistics published by the Government for the period 
since 1995.   
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Some figures have been published by EMCDDA and in ECCAS monograph on data 
provided on a consistent basis.  
 
The lack of detail and range of information collected by GMRs limits their usefulness 
for informing prevention and intervention strategies.  
 
These needs can be met by a SMR staffed by personnel with sufficient medical 
knowledge and experience of handling and interpreting such data, collecting data from 
a range of sources, using a case-matching approach. Having one centre leads to an 
informed and consistent approach to interpreting DRD data.   
 
Since July 1997 NPSAD has collected and published information on DRDs provided 
on a voluntary basis by most English and Welsh coroner's jurisdictions and by some in 
Northern Ireland. Discussions are being conducted to extend coverage across the UK.   
 
Range of information collected is wider than that of GMRs and is being extended to 
pathology and toxicology.   
 
Information and statistics produced by NPSAD fed into the work of the ACMD and 
TWG at national level, and will help to inform activities under the Government's Action 
Plan. Studies have been undertaken for Drug Action Teams (DATs) to help inform 
local policies and interventions. 
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UK Government's Action Plan on DRDs 
 
Action Plan on reducing DRDs announced 15 November 2001.  
 
The programme for England and Wales includes:  
(a) surveillance work to establish a baseline for monitoring success for action plan 
activities;  
(b) increased analysis of information from coroner's reports; provision of guidance 
and training to coroners;  
(c) provision of guidance to Drug Action Teams on running local inquiries into DRDs 
and running resuscitation training for drug users;  
(d) campaign work with users on highlighting the risks of overdose; and research 
work to improve information on causes of DRDs and inform methods of reducing 
them.  
 
These programmes, under the Government's Action Plan, will be overseen by a 
Steering Group comprising officials, academics and field experts, chaired by the 
National Treatment Agency.   
 
£1.9 million (Canadian $4.6 million) was made available to support these activities 
until 2003.  
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The 3-5 year programme is aimed at playing a key role in achieving the Government's 
objective of reducing DRDs by 20% by 2004, using a baseline from 1999 data.  
 
UK target is a reduction of about 400 in DRDs by 2004 (Table 1). This is against the 
background of a 31% increase across the UK in 1996-2000.   
 
The increases in the individual countries ranged from 20% to 61%.   
 
Initial signs are that may be an ambitious target; Scottish figures for 2001 indicate a 
14% rise (to 332) in the number of deaths in that country. 
 
The use of a broader definition of DRDs, such as the 'standard' one employed by the 
ONS, would lead to a different picture (Table 2).   
 
In 1996-2000 there was an overall increase of 9%, ranging from 3% in Scotland to 
35% in Northern Ireland.   
 
The Drug Strategy indicator, if expressed in terms of the ONS definition, would 
necessitate a reduction of 700 deaths by 2004 to meet the desired target.  This is 75% 
higher than would be required by the measure that has been adopted.   
 
This is a good example of how definitions can affect targets.  
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Table 1. DRDs using UK Drug Strategy definition, UK, 1996-2000 
 
 1996 1997 1998 1999 2000 % 
increas
e 1996-
2000 
2004 
(Target) 
Scotland 244 224 249 291 292 20 233 
England 1183 1237 1390 1480 1562 32 1184 
Wales 51 49 54 77 82 61 62 
Northern 
Ireland 
40 39 40 50 53 33 40 
United 
Kingdom 
1518 1549 1733 1898 1989 31 1518 
UK rate/million 
pop 
25.8 26.2 29.3 31.9 33.2   
Note: excludes non-residents. 
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Table 2. DRDs using ONS 'Standard', UK, 1996-2000 
 
 1996 1997 1998 1999 2000 % 
increas
e 1996-
2000 
2004 
(Target) 
England & 
Wales 
2721 2858 2922 2943 2968 9 2375 
Scotland 460 447 449 492 473 3 394 
Northern 
Ireland 
40 39 40 50 54 35 40 
United 
Kingdom 
3221 3344 3411 3485 3495 9 2788 
UK rate/million 
pop 
54.8 56.7 57.8 58.6 58.5   
Note: excludes non-residents. 
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Some conclusions 
 
Promising progress on defining and establishing baseline figures against which 
measurement of progress against the UK Drug Strategy target for reducing DRDs.   
 
Some areas still need addressing to improve the quality and breadth of information 
required.   
 
Standardised approaches must be developed by all those involved in investigating 
DRDs.  
 
Standardisation and consistency in recording, analysing and publishing data on DRDs 
are needed.   
 
Need to understand - 
 
- what, how and by whom data relating to DRDs are generated;  
- what happens to such data and how they are used in investigating deaths;  
- what ends up in published statistics.   
 
Such a research project would enable a model to be constructed to inform future 
policies and developments.  This is not only a UK need.  Both the ECCAS monograph 
and the Stockholm conference call for a European-wide initiative in this area. 
